

Subject ID	Cohort	Tumor Type	MSI Status	Germline mutations in MMR genes	Documented Lynch Syndrome	IHC	WHO/RECIST Response Rate	Radiographic Response (% change from baseline SLD)	Biochemical Response (% tumor marker change)
1	A	Colorectal	MSI	MSH-2 (splice)	Yes	Unknown	SD	-4	-79
3	B	Colorectal	MSS	None	No	Unknown	PD	55	586
4	C	Ampulla of Vater	MSI	MSH-2 (stop)	Yes	MSH-2, MSH-6	PD	56	336
6	C	Small Bowel	MSI	MSH-2 (stop)	Yes	MSH-2, MSH-6	PD	38	No Marker
7	B	Colorectal	MSS	None	No	Unknown	PD	35	55
8	A	Colorectal	MSI	None	No	hMLH-1	PR	-50	-99
9	A	Colorectal	MSI	None	Yes	Unknown	SD	2	-17
10	B	Colorectal	MSS	None	No	None	SD	6	74
11	A	Colorectal	MSI	MSH-2 (FS)	Yes	Unknown	SD	-7	-94
13	B	Colorectal	MSS	None	No	Unknown	PD	45	1939
14	B	Colorectal	MSS	None	No	Unknown	PD	16	478
15	A	Colorectal	MSI	None	Yes	MSH-2, MSH-6	PR	-35	-97
16	A	Colon/Duodenal	MSI	MLH-1 (FS)	Yes	Unknown	SD	-28	-94
17	B	Colorectal	MSS	None	No	Unknown	PD	40	65
18	B	Colorectal	MSS	None	No	None	PD	5	-7
19	A	Colorectal	MSI	None	No	hMLH-1, PMS2	PR	-35	-75
20	C	Ampulla of Vater	MSI	MSH2	Yes	MSH2,MSH6	PR	-73	-96
21	B	Colorectal	MSS	None	No	Unknown	PD	34	60
22	B	Colorectal	MSS	None	No	Unknown	SD	-14	-12
24	B	Colorectal	MSS	None	No	None	Clinical PD	2	No Marker
25	C	Duodenum	MSI	None	No	PMS2, MLH1	PR	-50	No Marker
26	B	Colorectal	MSS	None	No	Unknown	Clinical PD	-11	-4
27	B	Colorectal	MSS	None	No	Unknown	Clinical PD		11
28	B	Colorectal	MSS	None	No	None	PD	-14	-9
29	C	Endometrium	MSI	None	No	MHL-1, PMS 2	CR	-61	-93
30	C	Endometrium	MSI	None	No	MSH-2, MSH-6	PR	-70	-13
31	A	Colorectal	MSI	MLH-1	Yes	MSH-2, MSH-6, weak MLH 1	PR	-51	No Marker
32	B	Colorectal	MSS	None	No	Unknown	PD	16	No Marker
33	A	Colorectal	MSI	MSH-2	Yes	MSH-2, MSH-6	PD	7	28
35	C	Bile duct	MSI	None	No	MLH1;PMS2	PR	-41	-93
36	A	Colorectal	MSI	MLH-1	Yes	MLH1	SD	3	-64
37	B	Colorectal	MSS	None	No	Unknown	PD	26	-20
38	B	Colorectal	MSS	None	No	Unknown	Clinical PD	2	17
40	B	Colorectal	MSS	None	No	Unknown	Not evaluable		-37
41	B	Colorectal	MSS	None	No	Unknown	Clinical PD	-4	No Marker
42	A	Colorectal	MSI	Pending	Yes	Unknown	Not evaluable		-95
44	C	Ampulla of Vater	MSI	Pending	Yes	MSH-6	Not evaluable		No Marker
2.001	B	Colorectal	MSS	None	No	None	PD		306
2.002	B	Colorectal	MSS	None	No	None	Not evaluable		209
2.003	B	Colorectal	MSS	None	No	None	Not evaluable		46
2.004	C	Gastric	MSI	Pending	Unknown	MLH1, PMS2	Not evaluable		No Marker

<sup>1</sup>Only HLA A and B were used for neoantigen prediction

<sup>2</sup>5% or greater indicates significant PD-L1 expression on tumor cells

Subject ID	Cohort	Tumor Type	Patient HLA Haplotypes	HLA Haplotypes analyzed by for neoantigen prediction <sup>1</sup>	Total Somatic mutations	Mutations Resulting in an Amino Acid Change	Total Neoantigens	Total neoantigens per allele	Mutation-associated Neoantigens (MANAs)
1	A	Colorectal	A*29:02, A*74:01, B*18:01, B*50:01, C*06:02, C*07:04	2 out of 4	1291	777	349	175	120
3	B	Colorectal	A*33:01, B*07:05, B*15:03, C*02:10, C*07:02		Failed	-	-		-
4	C	Ampulla of Vater	A*02:01, A*26:01, B*35:01, B*38:01, C*04:01, C*12:03	4 out of 4	771	505	571	143	233
6	C	Small Bowel	A*02:01, B*07:02, B*15:01, C*03:04, C*07:02	3 out of 3	2138	1575	2494	831	791
7	B	Colorectal	A*11:01, A*24:02, B*07:02, C*07:02	3 out of 3	67	59	52	17	17
8	A	Colorectal	A*11:01, A*33:01, B*14:02, C*08:02	3 out of 3	1681	1016	1200	400	322
9	A	Colorectal	A*02:01, A*31:01, B*07:02, B*51:01, C*07:02, C*15:02	4 out of 4	1814	1222	2326	582	626
10	B	Colorectal	A*23:01, A*26:01, B*38:01, B*44:03, C*04:01, C*12:03	4 out of 4	118	105	68	17	22
11	A	Colorectal	A*02:01, A*03:01, B*15:01, B*44:02, C*03:04, C*04:01	4 out of 4	492	328	533	133	214
13	B	Colorectal	A*02:01, A*24:02, B*27:02, B*51:01, C*02:02	4 out of 4	5	5	10	3	2
14	B	Colorectal	A*01:01, A*68:02, B*14:02, B*37:01, C*07:01, C*08:02		Failed	-	-		-
15	A	Colorectal	A*02:03, A*11:01, B*15:01, B*18:01, C*04:01, C*07:04	4 out of 4	2345	1476	3506	877	1029
16	A	Colon/Duodenal	A*03:01, A*11:01, B*15:18, B*35:01, C*04:01, C*07:04	4 out of 4	4025	2287	3928	982	1221
17	B	Colorectal	A*01:01, A*30:01, B*08:01, B*13:02, C*06:02, C*07:01	3 out of 4	70	65	69	23	22
18	B	Colorectal	A*02:01, A*68:01, B*44:02, C*05:01		Failed	-	-		-
19	A	Colorectal	A*01:01, A*31:01, B*08:01, B*35:01, C*04:01, C*07:01	4 out of 4	1477	770	1011	253	654
20	C	Ampulla of Vater	Not Done		Not Done				
21	B	Colorectal	A*01:01, A*02:01, B*51:01, B*55:01, C*03:03, C*14:02	3 out of 4	77	72	59	20	20
22	B	Colorectal	A*23:01, A*68:01, B*35:01, B*40:01, C*03:04, C*04:01	3 out of 4	102	96	160	40	45
24	B	Colorectal	Not Done		Not Done				
25	C	Duodenum	A*03:01, A*25:01, B*07:02, B*18:01, C*07:02, C*12:03		Not Done	-	-		-
26	B	Colorectal	A*11:01, A*24:02, B*18:01, B*57:01, C*06:02, C*07:02		Not Done	-	-		-
27	B	Colorectal	A*01:02, A*24:02, B*07:02, B*58:02, C*06:02, C*07:02		Not Done	-	-		-
28	B	Colorectal	A*03:01, B*07:02, B*14:02, C*07:02, C*08:02		Not Done	-	-		-
29	C	Endometrium	A*01:01, A*03:01, B*07:02, B*37:01, C*06:02, C*07:02		Not Done	-	-		-
30	C	Endometrium	A*24:02, A*26:01, B*35:02, C*04:01		Not Done	-	-		-
31	A	Colorectal	A*11:01, A*24:02, B*35:02, B*52:01, C*04:01, C*12:02		Not Done	-	-		-
32	B	Colorectal	A*01:01, A*02:01, B*44:02, B*57:01, C*05:01, C*06:02		Not Done	-	-		-
33	A	Colorectal	A*02:01, A*26:01, B*13:02, B*27:05, C*02:02, C*06:02		Not Done	-	-		-
35	C	Bile duct	Not Done		Not Done				
36	A	Colorectal	A*02:01, A*29:02, B*44:02, B*44:03, C*02:02, C*16:01		Not Done	-	-		-
37	B	Colorectal	Not Done		Not Done				
38	B	Colorectal	A*01:01, A*02:01, B*08:01, B*44:02, C*05:01, C*07:01		Not Done	-	-		-
40	B	Colorectal	A*01:01, A*26:01, B*07:02, B*44:02, C*05:01, C*07:02		Not Done	-	-		-
41	B	Colorectal	Not Done		Not Done				
42	A	Colorectal	Not Done		Not Done				
44	C	Ampulla of Vater	Not Done		Not Done				
2.001	B	Colorectal	Not Done		Not Done				
2.002	B	Colorectal	Not Done		Not Done				
2.003	B	Colorectal	Not Done		Not Done				
2.004	C	Gastric	Not Done		Not Done				

<sup>1</sup>Only HLA A and B were used for neoantigen

<sup>2</sup>5% or greater indicates significant PD-L1 ex

Subject ID	Cohort	Tumor Type	PD-L1 Expression on TILs and Macrophages invasive front (%)	PD-L1 Expression on TILs (%)	CD8 density in tumor (mm2)	CD8 density at Invasive front (mm2)	CD8 density in non-tumor tissue (mm2)	Reason Off Study
1	A	Colorectal	40	10	227	363	0	Trousseau's Syndrome (unrelated)
3	B	Colorectal	0	0	23	73	0	Disease Progression
4	C	Ampulla of Vater	5	5	16	209	0	Disease Progression
6	C	Small Bowel	0	0	Failed	Failed	Failed	Disease Progression
7	B	Colorectal	Failed	Failed	Failed	Failed	Failed	Disease Progression
8	A	Colorectal	0	0	5	64	0	N/A
9	A	Colorectal	75	25	91	407	0	Disease Progression
10	B	Colorectal	20	20	335	227	0	Asymptomatic grade 2 pancreatitis (grade 3 amylase/lipase) (related)
11	A	Colorectal	0	0	32	282	0	N/A
13	B	Colorectal	Failed	Failed	0	77	0	Disease Progression
14	B	Colorectal	Failed	Failed	Failed	Failed	Failed	Disease Progression
15	A	Colorectal	15	20	162	72	0	N/A
16	A	Colon/Duodenal	75	5	298	673	0	N/A
17	B	Colorectal	5	10	Failed	Failed	Failed	Disease Progression
18	B	Colorectal	5	5	144	343	0	Disease Progression
19	A	Colorectal	40	10	1009	582	Failed	N/A
20	C	Ampulla of Vater						N/A
21	B	Colorectal	1	0	38	308	0	Disease Progression
22	B	Colorectal	Failed	Failed	Failed	Failed	Failed	Disease Progression
24	B	Colorectal						Disease Progression
25	C	Duodenum	Failed	10	623	Failed	Failed	N/A
26	B	Colorectal	0	0	Failed	Failed	Failed	Disease Progression
27	B	Colorectal	0	0	71	194	0	Disease Progression
28	B	Colorectal	0	0	114	259	0	N/A
29	C	Endometrium	Failed	5	870	Failed	Failed	N/A
30	C	Endometrium	70	30	347	1215	0	N/A
31	A	Colorectal	0	0	7	13	Failed	N/A
32	B	Colorectal	10	5	72	146	0	Disease Progression
33	A	Colorectal	0	5	32	891	0	N/A
35	C	Bile duct						N/A
36	A	Colorectal	5	5	205	1192	0	N/A
37	B	Colorectal						Disease Progression
38	B	Colorectal	0	0	127	463	0	Disease Progression
40	B	Colorectal	5	10	50	27	0	N/A
41	B	Colorectal						Disease Progression
42	A	Colorectal						N/A
44	C	Ampulla of Vater						Disease Progression
2.001	B	Colorectal						Disease Progression
2.002	B	Colorectal						N/A
2.003	B	Colorectal						N/A
2.004	C	Gastric						N/A

<sup>1</sup>Only HLA A and B were used for neoantigen

<sup>2</sup>5% or greater indicates significant PD-L1 ex